SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sandu Pharmaceuticals informs about press release

18 Oct 2025 Evaluate
Sandu Pharmaceuticals has enclosed copy of Newspaper Advertisement published in the 'Navprabha' (English) and `Navprabha' (Marathi) newspapers, dated 18th October 2025 for Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97, dated July 02, 2025 and Launch of ‘Saksham Niveshak’ Campaign - Action Required for Unclaimed Dividends and KYC Updates. 

The above information is a part of company’s filings submitted to BSE.



Sandu Pharmaceutical Share Price

36.49 0.23 (0.63%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×